Servier, an independent international pharmaceutical group, and the SATT Network are extending their partnership, which began in 2020, to identify new therapeutic opportunities from public research laboratories and DeepTech start-ups. The areas of research concerned are oncology, neurology, and immuno-inflammation.
SATT Paris-Saclayremains the point of contact for this partnership within the SATT Network, given that the futureServierResearch and Development Institute will be established in Paris-Saclay in 2023.
Therapeutic scouting supports Servier Group's open innovation dynamic
The scouting system set up by the SATT Network makes it possible to identify therapeutic projects at an early stage that meet the R&D needs of the Servier group. It is a fast and coordinated way to access innovation thanks to the network of 13 SATTs.
"In 2020, we were able to discuss with the Servier group several dozen healthcare projects identified by SATTs in academic research laboratories and in which SATTs have invested. Drawing on its industrial approach, Servier's external innovation team identified therapeutic opportunities among these projects that offer high added value in terms of innovation. These discussions will accelerate the transfer of technologies from SATTs, whether to a start-up or a biotech company," explainsSandrine Gary-Tréhin, Head of Scouting at SATT Paris-Saclay and member of the SATT Network.
A strategic partnership to strengthen ties with French public research
"Scouting allows us to identify projects that we would not have been able to identify otherwise. The goal is to feed our pipeline of innovative therapeutic projects and interact with the research teams and deep tech start-ups in charge of these projects," adds Isabelle Dupin-Roger, Director of External Innovation in Immuno-Inflammation and Neurology at Servier, in charge of scouting with the SATT Network. "The relationships of trust we have established with the SATT Network and SATT Paris-Saclay allow us to envisage a fruitful partnership in the longer term."